Mounzer Agha

Associate Professor

University of Pittsburgh

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Mounzer Agha is an Associate Professor at the University of Pittsburgh, USA. His research focuses on hematologic malignancies, specifically multiple myeloma and acute myeloid leukemia, with recent contributions to the understanding of innovative therapies such as CAR T-cell therapy. He has published extensively on topics including the clinical outcomes of synthetic therapies and complications associated with hematologic treatments.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (6)

Abdullah Khan

Assistant Professor

Ohio State University

UNITED STATES

View details

Irene Ghobrial

Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES

View details

Janet S. Lee

University of Pittsburgh

UNITED STATES

View details

Aurore Perrot

Professor of Hematology

Université Paul Sabatier

FRANCE

View details

Larry Anderson

Professor

University of Texas Southwestern Medical Center

UNITED STATES

View details

Ashwin Somasundaram

Assistant Professor of Medicine

University of North Carolina at Chapel Hill

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Mounzer Agha

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

Outcomes of Patients With Acute Myeloid Leukemia Who Relapse After 5 Years of Complete Remission

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study

Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature

Collaborators (6)

Abdullah Khan

Irene Ghobrial

Janet S. Lee

Aurore Perrot

Larry Anderson

Ashwin Somasundaram

Make your next move.